EGFR and non-small cell lung carcinoma: For example, enrolment of patients into the phase III INSPIRE trial, which evaluated the addition of the anti-EGFR antibody necitumumab to cisplatin-based chemotherapy in patients with metastatic NSCLC, was stopped due to an excess of fatal and nonfatal thromboembolic events and overall number of deaths in the experimental arm [11].